News >

Leveraging Limited Data in Metastatic Pancreatic Cancer

Caroline Seymour
Published: Thursday, Mar 21, 2019

Damian Laber, MD

Damian Laber, MD

Although both regimens carry added toxicities, FOLFIRINOX and the combination of gemcitabine and nab-paclitaxel (Abraxane) have each been shown to improve survival over gemcitabine alone for patients with metastatic pancreatic cancer, said Damian Laber, MD.

State of the Science Summit™ on Gastrointestinal Malignancies, Laber, hematologist/oncologist and senior member of Moffitt Cancer Center, provided a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shared his hope for the future of the treatment paradigm.

OncLive: Could you discuss the trials that led to current frontline approaches?

Laber: It took many years [to establish FOLFIRINOX as a frontline treatment for patients with metastatic pancreatic cancer]. In 2011, a study was published comparing gemcitabine with FOLFIRINOX; patients in that study had not received prior chemotherapy. They had to have locally advanced or metastatic disease and were not candidates for curative therapy; the randomization was done fairly well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x